Liping Li

Liping Li

Auto-generated profile, based on publicly available information

Liping Li

Department of Physiology and Pharmacology, Health Science Center, Ningbo University, Ningbo, Zhejiang 315211, PR China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2020 in Journal of Neurochemistry
Verified
Journal Article
Closed access
PDF file
LLLiping Li
Liping Li
MMMiao Miao
Miao Miao
JCJiarui Chen
Jiarui Chen
ZLZhitao Liu
Zhitao Liu
WLWanyi Li
Wanyi Li
QWQinwen Wang
Qinwen Wang

29 July 2024 in Neural Regeneration Research
Verified
Journal Article
Open access
BXBiao Xiao
Biao Xiao
CCChaoyang Chu
Chaoyang Chu
ZLZhicheng Lin
Zhicheng Lin
TFTianyuan Fang
Tianyuan Fang
YZYuyu Zhou
Yuyu Zhou
LLLiping Li
Liping Li
JOURNAL/nrgr/04.03/01300535-202509000-00031/figure1/v/2026-04-27T065306Z/r/image-tiff A reduction in adult neurogenesis is associated with behavioral abnormalities in patients with Alzheimer’s disease. Consequently, enhancing adult neurogenesis represents a promising therapeutic approach for mitigating disease symptoms and progression. Nonetheless, non-pharmacological interventions aimed at inducing adult neurogenesis are currently limited. Although individual non-pharmacological interventions, such as aerobic exercise, acousto-optic stimulation, and olfactory stimulation, have shown limited capacity to improve neurogenesis and cognitive function in patients with Alzheimer’s disease, the therapeutic effect of a strategy that combines these interventions has not been fully explored. In this study, we observed an age-dependent decrease in adult neurogenesis and a concurrent increase in amyloid-beta accumulation in the hippocampus of amyloid precursor protein/presenilin 1 mice aged 2–8 months. Amyloid deposition became evident at 4 months, while neurogenesis declined by 6 months, further deteriorating as the disease progressed. However, following a 4-week multifactor stimulation protocol, which encompassed treadmill running (46 min/d, 10 m/min, 6 days per week), 40 Hz acousto-optic stimulation (1 hour/day, 6 days/week), and olfactory stimulation (1 hour/day, 6 days/week), we found a significant increase in the number of newborn cells (5′-bromo-2′-deoxyuridine–positive cells), immature neurons (doublecortin-positive cells), newborn immature neurons (5′-bromo-2′-deoxyuridine-positive/doublecortin-positive cells), and newborn astrocytes (5′-bromo-2′-deoxyuridine-positive/glial fibrillary acidic protein–positive cells). Additionally, the amyloid-beta load in the hippocampus decreased. These findings suggest that multifactor stimulation can enhance adult hippocampal neurogenesis and mitigate amyloid-beta neuropathology in amyloid precursor protein/presenilin 1 mice. Furthermore, cognitive abilities were improved, and depressive symptoms were alleviated in amyloid precursor protein/presenilin 1 mice following multifactor stimulation, as evidenced by Morris water maze, novel object recognition, forced swimming test, and tail suspension test results. Notably, the efficacy of multifactor stimulation in consolidating immature neurons persisted for at least 2 weeks after treatment cessation. At the molecular level, multifactor stimulation upregulated the expression of neuron-related proteins (NeuN, doublecortin, postsynaptic density protein-95, and synaptophysin), anti-apoptosis–related proteins (Bcl-2 and PARP), and an autophagy-associated protein (LC3B), while decreasing the expression of apoptosis-related proteins (BAX and caspase-9), in the hippocampus of amyloid precursor protein/presenilin 1 mice. These observations might be attributable to both the brain-derived neurotrophic factor-mediated signaling pathway and antioxidant pathways. Furthermore, serum metabolomics analysis indicated that multifactor stimulation regulated differentially expressed metabolites associated with cell apoptosis, oxidative damage, and cognition. Collectively, these findings suggest that multifactor stimulation is a novel non-invasive approach for the prevention and treatment of Alzheimer’s disease.

17 March 2022 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
WLWan-Yi Li
Wan-Yi Li
JGJun-Yan Gao
Jun-Yan Gao
SLSu-Yang Lin
Su-Yang Lin
SPShao-Tao Pan
Shao-Tao Pan
BXBiao Xiao
Biao Xiao
LLLi-Ping Li
Li-Ping Li

17 June 2021 in Plant Physiology
Verified
Journal Article
Open access
PDF file
QFQingkai Feng
Qingkai Feng
LLLiping Li
Liping Li
YLYan Liu
Yan Liu
XSXingfeng Shao
Xingfeng Shao
XLXiaohui Li
Xiaohui Li
Myrosinases are β-thioglucoside glucosidases that are unique to the Brassicales order. These enzymes hydrolyze glucosinolates to produce compounds that have direct antibiotic effects or that function as signaling molecules in the plant immune system, protecting plants from pathogens and insect pests. However, the effects of jasmonic acid (JA), a plant hormone that is crucial for plant disease resistance, on myrosinase activity remain unclear. Here, we systematically studied the effects of JA on myrosinase activity and explored the associated internal transcriptional regulation mechanisms. Exogenous application of JA significantly increased myrosinase activity, while the inhibition of endogenous JA biosynthesis and signaling reduced myrosinase activity. In addition, some myrosinase genes in Arabidopsis (Arabidopsis thaliana) were upregulated by JA. Further genetic and biochemical evidence showed that transcription factor FAMA interacted with a series of JASMONATE ZIM-DOMAIN proteins and affected JA-mediated myrosinase activity. However, among the JA-upregulated myrosinase genes, only THIOGLUCOSIDE GLUCOHYDROLASE 1 (TGG1) was positively regulated by FAMA. Further biochemical analysis showed that FAMA bound to the TGG1 promoter to directly mediate TGG1 expression in conjunction with Mediator complex subunit 8 (MED8). Together, our results provide evidence that JA acts as an important signal upstream of the FAMA/MED8–TGG1 pathway to positively regulate myrosinase activity in Arabidopsis.

1 August 2023 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
JGJunyan Gao
Junyan Gao
LLLiping Li
Liping Li
Alzheimer's disease (AD), the most common cause of dementia worldwide, has gradually become a global health concern for society and individuals with the process of global ageing. Although extensive research has been carried out on AD, the etiology and pathological mechanism of the disease are still unclear, and there is no specific drug to cure or delay AD progression. The exploration of enhancing nerve regeneration in AD has gradually attracted increasing attention. In the current review, the existing therapeutic strategies were summarized to induce nerve regeneration which can increase the number of neurons, and improve the survival of neurons, the plasticity of synapses and synaptic activity. The strategies include increasing neurotrophic expression (such as brain‑derived neurotrophic factor and nerve growth factor), inhibiting acetylcholinesterase (such as donepezil, tacrine, rivastigmine and galanthamine), elevating histone deacetylase levels (such as RGFP‑966, Tasquinimod, CM‑414 and 44B), stimulating the brain by physiotherapy (such as near‑infrared light, repetitive transcranial magnetic stimulation, and transcranial direct current stimulation) and transplanting exogenous neural stem cells. However, further evaluations need to be performed to determine the optimal treatment. The present study reviews recent interventions for enhancing adult neurogenesis and attempts to elucidate their mechanisms of action, which may provide a theoretical basis for inducing nerve regeneration to fight against AD.

8 March 2022 in Neurochemistry International
Verified
Journal Article
Closed access
ZLZhi-Tao Liu
Zhi-Tao Liu
YMYu-Tao Ma
Yu-Tao Ma
SPShao-Tao Pan
Shao-Tao Pan
KXKai Xie
Kai Xie
WSWei Shen
Wei Shen
LLLi-Ping Li
Li-Ping Li